GS
PACB icon

GTS Securities’s Pacific Biosciences PACB Stock Holding History

GTS Securities’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3K Sell
10,896
-6,237
-36% -$9.07K ﹤0.01% 1300
2026
Q1 		$22.6K Buy
+17,133
New +$30.7K ﹤0.01% 1456
2025
Q4 		– Sell
-45,306
Closed -$58K – 1682
2025
Q3 		$58K Buy
+45,306
New +$61.4K ﹤0.01% 1371
2025
Q2 		– Sell
-12,509
Closed -$14.8K – 1503
2025
Q1 		$14.8K Buy
+12,509
New +$19.2K ﹤0.01% 1202
2024
Q4 		– Sell
-20,188
Closed -$34.3K – 3229
2024
Q3 		$34.3K Sell
20,188
-13,801
-41% -$22.7K ﹤0.01% 3928
2024
Q2 		$46.6K Sell
33,989
-3,456
-9% -$6.98K ﹤0.01% 3713
2024
Q1 		$140K Sell
37,445
-279,090
-88% -$1.63M ﹤0.01% 3451
2023
Q4 		$3.11M Buy
316,535
+95,943
+43% +$785K 0.01% 1327
2023
Q3 		$1.84M Buy
220,592
+12,793
+6% +$146K ﹤0.01% 1576
2023
Q2 		$2.76M Buy
+207,799
New +$2.53M 0.09% 213

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GTS Securities's PACB Position: Q2 2026 in Review

GTS Securities reduced its Pacific Biosciences (PACB) stake by 36% in Q2 2026, selling an estimated $9.07K and leaving 10,896 shares worth $18.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1300.

GTS Securities first reported a position in PACB in Q2 2023 and has held it in 10 quarters since. The position peaked at $3.11M in Q4 2023. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • GTS Securities held 10,896 shares of Pacific Biosciences worth $18.3K as of Q2 2026.
  • GTS Securities sold 6,237 Pacific Biosciences shares in Q2 2026, an estimated $9.07K.
  • Pacific Biosciences made up ﹤0.01% of GTS Securities's portfolio in Q2 2026, its #1300 holding.
  • GTS Securities first reported a position in Pacific Biosciences in Q2 2023 and has held it in 10 quarters since.
  • GTS Securities's Pacific Biosciences position peaked at $3.11M in Q4 2023.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.